-
1
-
-
15644380122
-
Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy
-
Marcellin P, Boyer N, Gervais A, et al,. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 1997; 127: 875-881.
-
(1997)
Ann Intern Med
, vol.127
, pp. 875-881
-
-
Marcellin, P.1
Boyer, N.2
Gervais, A.3
-
2
-
-
0033058754
-
Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon
-
Reichard O, Glaumann H, Fryden A, Norkrans G, Wejstal R, Weiland O,. Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon. J Hepatol 1999; 30: 783-787.
-
(1999)
J Hepatol
, vol.30
, pp. 783-787
-
-
Reichard, O.1
Glaumann, H.2
Fryden, A.3
Norkrans, G.4
Wejstal, R.5
Weiland, O.6
-
3
-
-
79957497436
-
A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C
-
Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA,. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol 2011; 9: 509-516.
-
(2011)
Clin Gastroenterol Hepatol
, vol.9
, pp. 509-516
-
-
Backus, L.I.1
Boothroyd, D.B.2
Phillips, B.R.3
Belperio, P.4
Halloran, J.5
Mole, L.A.6
-
4
-
-
0035934568
-
Peginterferon α-2b plus ribavirin compared with interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial
-
Manns MP, McHutchison JG, Gordon SC, et al,. Peginterferon α-2b plus ribavirin compared with interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965.
-
(2001)
Lancet
, vol.358
, pp. 958-965
-
-
Manns, M.P.1
McHutchison, J.G.2
Gordon, S.C.3
-
5
-
-
0032547944
-
Interferon α-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C
-
Davis GL, Esteban-Mur R, Rustgi V, et al,. Interferon α-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998; 339: 1493-1499.
-
(1998)
N Engl J Med
, vol.339
, pp. 1493-1499
-
-
Davis, G.L.1
Esteban-Mur, R.2
Rustgi, V.3
-
6
-
-
0032547938
-
Interferon α-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
-
McHutchison JG, Gordon SC, Schiff ER, et al,. Interferon α-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 1485-1492.
-
(1998)
N Engl J Med
, vol.339
, pp. 1485-1492
-
-
McHutchison, J.G.1
Gordon, S.C.2
Schiff, E.R.3
-
7
-
-
0032585237
-
Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
-
Poynard T, Marcellin P, Lee SS, et al,. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352: 1426-1432.
-
(1998)
Lancet
, vol.352
, pp. 1426-1432
-
-
Poynard, T.1
Marcellin, P.2
Lee, S.S.3
-
8
-
-
17844403232
-
A randomized, double-blind trial comparing pegylated interferon α-2b to interferon α-2b as initial treatment for chronic hepatitis C
-
Lindsay KL, Trepo C, Heintges T, et al,. A randomized, double-blind trial comparing pegylated interferon α-2b to interferon α-2b as initial treatment for chronic hepatitis C. Hepatology 2001; 34: 395-403.
-
(2001)
Hepatology
, vol.34
, pp. 395-403
-
-
Lindsay, K.L.1
Trepo, C.2
Heintges, T.3
-
9
-
-
33645968702
-
Sustained virological response rates and durability of the response to interferon-based therapies in hepatitis C patients treated in the clinical setting
-
Desmond CP, Roberts SK, Dudley F, et al,. Sustained virological response rates and durability of the response to interferon-based therapies in hepatitis C patients treated in the clinical setting. J Viral Hepat 2006; 13: 311-315.
-
(2006)
J Viral Hepat
, vol.13
, pp. 311-315
-
-
Desmond, C.P.1
Roberts, S.K.2
Dudley, F.3
-
10
-
-
74049109303
-
Sustained virological response to pegylated interferon and ribavirin is maintained during long-term follow-up of chronic hepatitis C patients
-
Giannini EG, Basso M, Savarino V, Picciotto A,. Sustained virological response to pegylated interferon and ribavirin is maintained during long-term follow-up of chronic hepatitis C patients. Aliment Pharmacol Ther 2010; 31: 502-508.
-
(2010)
Aliment Pharmacol Ther
, vol.31
, pp. 502-508
-
-
Giannini, E.G.1
Basso, M.2
Savarino, V.3
Picciotto, A.4
-
11
-
-
78049476361
-
A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon α-2a and ribavirin
-
Swain MG, Lai MY, Shiffman ML, et al,. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon α-2a and ribavirin. Gastroenterology 2010; 139: 1593-1601.
-
(2010)
Gastroenterology
, vol.139
, pp. 1593-1601
-
-
Swain, M.G.1
Lai, M.Y.2
Shiffman, M.L.3
|